Eli Lilly's weight-loss drug misses Wall Street expectations, shares tumble
Lilly's shares fell over 10% due to lower-than-expected drug sales
CEO David Ricks cited excess supply and delayed advertising for the shortfall
Lilly slashes annual profit forecast due to acquisition charges and higher costs
Adds background on shortage in paragraphs 13-14 and analyst comment in paragraph 10; updates shares
By Bhanvi Satija and Patrick Wingrove
Oct 30 (Reuters) -Sales of Eli Lilly's LLY.N high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as wholesalers worked through their existing supply of the treatments instead of placing new orders, and its shares fell more than 10%.
Lilly has been posting strong earnings for several quarters on high demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro. Drug wholesalers purchase medicines like Zepbound directly from manufacturers and sell them to hospitals, clinics, pharmacies and other healthcare providers.
The company delayed plans to advertise Zepbound and held back on international launches to focus on increasing inventory levels in the U.S., CEO David Ricks told CNBC.
"There is an excess supply... but we haven't been stimulating demand the way we had originally planned," Ricks said.
Sales of Mounjaro were $3.11 billion, while Zepbound brought in $1.26 billion, which Lilly said reflected continued strong demand.
Analysts were looking for sales of $4.20 billion for Mounjaro and $1.69 billion for Zepbound for the quarter, according to LSEG data. They expect the drugs to make a combined $19 billion this year.
Lilly's shares are up 55% so far this year, making it the world's most valuable healthcare company, as investors bet on the success of the weight-loss drug.
Mounjaro and Zepbound compete with Novo Nordisk's NOVOb.CO popular Ozempic and Wegovy. Novo, whose U.S. listed shares were also down by 3.4%, has been aggressively marketing Wegovy on U.S. television.
J.P. Morgan analyst Chris Schott said the results suggested wholesalers had utilized their existing inventories without placing additional new orders as analysts had expected.
The Indianapolis-based drugmaker also slashed its annual adjusted profit forecast to $13.02 to $13.52 per share, compared to prior view of $16.10 to $16.60, citing acquisition charges in the third quarter.
The previously disclosed $2.8 billion acquisition-related charge and higher manufacturing costs also contributed to the third-quarter profit miss.
Zepbound and Mounjaro were in short supply for much of this year due to soaring demand for the medicines that have been shown to help patients lose an average of 20% of their weight. Lilly said supply had started to catch up with demand last quarter, and it was able to backfill orders and increase stocks at U.S. wholesalers.
Lilly has since said its drugs were no longer in shortage. While the FDA also removed Lilly's drugs from its shortage list in late September, the agency is currently reviewing that decision.
Lilly has invested billions of dollars to expand production of Mounjaro and Zepbound, both known chemically as tirzepatide, including about $7 billion in its Indiana site and facilities in Ireland. The drug is sold under the brand name Mounjaro for both diabetes and weight loss outside the U.S.
Lilly trimmed the upper end of its full-year sales forecast by $600 million to $46 billion. It maintained the lower end at $45.4 billion.
Lilly and Novo Nordisk are racing to increase capacity and meet unprecedented demand for a weight-loss market some analysts estimate could reach $150 billion in annual revenue by the next decade.
In August, Novo trimmed its full-year profit forecast and reported a rare miss on quarterly sales of Wegovy.
Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Patrick Wingrove in New York; Editing by Sriraj Kalluvila and Bill Berkrot
Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
